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One of the key features of tumor cells is the acquisition of resistance to apoptosis. Thus, novel therapeutic
strategies that circumvent apoptotic resistance and result in tumor elimination are needed. One strategy
to induce apoptosis is to activate death receptor signaling pathways. In the tumor microenvironment,
stimulation of Fas, Death receptor 4 (DR4) and tumor necrosis factor receptor 1 (TNFR1) can initiate
multiple signaling pathways driving either tumor promotion or elimination. Nitric oxide (NO) is an
important signaling molecule now understood to play a dual role in cancer biology. More and more
attention is directed toward the role displayed by S-nitrosylation, the incorporation of an NO moiety to a
cysteine thiol group, in promoting cell death in tumor cells. Protein post-translation modiﬁcation by
S-nitrosylation has decisive roles in regulating signal-transduction pathways. In this review, we sum-
marize several examples of protein modiﬁcation by S-nitrosylation that regulate signaling pathways
engaged by members of the TNF superfamily (Fas ligand (FasL), Tumor-necrosis-factor-related apoptosis
inducing ligand (TRAIL) and TNFalpha (TNFα)) and the way it inﬂuences cell fate decisions.
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Signaling through members of tumor necrosis factor (TNF)
superfamily ligands and their receptors is required for normal
physiological responses including differentiation, survival, pro-
liferation and cell death.
It has been well established over the last three decades that
TNF superfamily signaling is a double-edged sword in cancernder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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one of the largest family of cytokines until now including 19 dif-
ferent ligands and nearly 30 receptors [1]. TNF superfamily cyto-
kines such as Fas ligand (FasL), TNF-related apoptosis inducing
ligand (TRAIL) and TNFalpha (TNFα) can originate from various
types of cells, immune and non-immune cells, within the tumor
microenvironment. It is generally assumed that protumoral and
antitumoral signaling coexist in the tumor microenvironment. The
abundance of innate and adaptive immune cells in the tumor
microenvironment and the expression of members of the TNF
superfamily cytokines contribute to dictate whether tumor cells
are more likely to proliferate or die.
Cell fate decisions leading to either protumoral or antitumoral
effects are linked to transcriptional gene expression changes and/
or protein post-translational modiﬁcations. Post-translational
modiﬁcation (PTM) is a key feature that mediates signal trans-
duction. The modiﬁcation of proteins by PTM allows the regulation
of protein properties and function. TNF superfamily signal-trans-
duction pathways rely on multiple PTM, phosphorylation and
ubiquitination being among the best documented. A large number
of studies have provided evidence that PTM by S-nitrosylation
modulates signal transduction upon certain stimuli just like
phosphorylation.
S-nitrosylation is a non-enzymatic process by which nitric oxideFig. 1. S-nitrosylation in TRAIL/DR4 and FaL/Fas signaling pathways. NO affects several
receptor DR4 and Fas have been shown to be S-nitrosylated in their cytoplasmic domain
inhibitor of Fas, is also shown to be S-nitrosylated upon NO donnor treatment. This S-n
transduction. NO inhibits caspase 3 or 9. More recently, the S-nitrosylation of cFLIP, an in
by the proteasome, thereby making it a more potent inhibitor of Fas and DR4 signaling. S
pathway leading to cell proliferation and survival.(NO) modulates the function of various target proteins. It consists on
the covalent incorporation of an NO moiety to a reactive thiol group
in speciﬁc cysteine residues. The S-nitrosylation of proteins is rela-
tively unstable and can be reversed by denitrosylation reaction
through now well established enzymatic systems such as thior-
edoxins (Trxs) and S-nitrosoglutathione reductase (GSNOR) [14,36].
The property of the thiol group of the cysteine also makes it a pri-
vileged site for a variety of other PTM such as S-palmitoylation,
S-glutathionylation, and S-sulfhydration [17]. So a mutually compe-
titive but also cooperative relationship between these PTM and
S-nitrosylation can exist depending on the redox environment. A link
between S-nitrosylation and S-glutathionylation (for review see
[41,43] seems to be established supporting the notion that NO and
S-nitrosylated proteins can be involved in S-glutathionylation for-
mation. In line with this, NO has been reported to mediate c-Jun
S-glutathionylation and inhibition [29].
More particularly, S-nitrosylation can affect protein structure
and function in many different ways by modulating enzymatic
activities, protein–protein interaction, protein subcellular location
or even the level of expression of proteins in cells [15,32,46].
Thereby, S-nitrosylation has emerged as critical physiological
regulators of a wide range of intracellular signaling pathways.
Here we review how S-nitrosylation regulates some of the
TNF-superfamily signaling pathways. We focus on the signalingproteins in death receptor-mediated apoptotic pathways. Among them, the TRAIL-
thereby increasing their activity to trigger apoptosis of target cells. The Ying Yang 1,
itrosylation inhibits its activity toward Fas and permits dowstream apoptotic signal
hibitor of Fas and DR4 signaling pathway has been shown to inhibit its degradation
-nitrosylated cFLIP will bind to RIP1 and subsequently activate the NF-KB signaling
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receptors (Fas, Death receptor 4 (DR4) and tumor necrosis factor
receptor 1 (TNFR1)) and the manner in which S-nitrosylation
mediates cancer cell death along signaling cascades.2. TNF-superfamily signaling pathways and apoptosis: role of
DR4 and Fas
Two main signaling pathways leading to the apoptotic machinery
are now well established: the intrinsic and extrinsic pathways. After
FasL and TRAIL binding to their cognate receptor and receptor tri-
merization, the trimer recruits the adaptor protein Fas-Associated
protein with Death Domain (FADD), then the initiator caspase-8
and/or -10 resulting in the formation of death-inducing signaling
complex (DISC) (Fig. 1). Activation of caspase-8 and/or -10 can trigger
subsequent activation of downstream caspase-3 that ultimately leads
to cell death via the extrinsic pathway [66]. A cross-talk exists be-
tween extrinsic and intrinsic pathway which requires initiator cas-
pase-dependent cleavage of the pro-apoptotic arm of the B-cell
lymphoma-2 (Bcl-2) gene superfamily permitting the release of cy-
tochrome c and ATP from mitochondria promoting the formation of
the apoptosome, resulting in additional caspase activation that col-
lectively leads to cell apoptosis. Upon ligand binding, most of the
death-receptors aggregate at the plasma membrane and more par-
ticularly in raft nanodomains enriched in cholesterol and glyco-
sphingolipids [11,16,19]. Some of these receptors may undergo a
variety of post-translational modiﬁcations including S-palmitoylation
and S-nitrosylation.
2.1. S-nitrosylation of TRAIL receptor DR4
DR4 is considered as a tumor-suppressor protein. Thus, the in-
crease in its expression and/or its aggregation is a major challenge in
cancer research. Over the two last decades, nitric oxide has emerged as
a potent antiproliferative and pro-apoptotic molecule against several
cancer cell lines involving TRAIL signaling through DR4 for example.
NO donor nitrosylcobalamin (NO-Cbl) (an analog of vitamin B12 that
delivers NO) has demonstrated a potent antiproliferative activity in
several human cell lines from different origins (melanoma, renal, and
ovarian carcinomas) [61]. This effect is triggered through the ability of
NO-Cbl to S-nitrosylate DR4 (but not Death receptor 5 (DR5)). Cysteine
residue 336 (C336) was characterized to be targeted by NO, and cells
expressing a C336A mutant form of DR4, which lacked S-nitrosylation,
were resistant to NO-Cbl-mediated cell growth inhibition. Of note, DR4
did not exhibit the linear consensus motif for the S-nitrosylation of
proteins [58]; however, it may exist in the three-dimensional structure
of DR4 but not of DR5 that could explain the discrepancy between the
two receptors. Interestingly, S-nitrosylation of DR4 has not been ob-
served with other NO donors such as S-nitroso-N-acetylpenicillamine
(SNAP) and 2, 2′-(hydroxynitrosohydrazono)bis-ethanamine (NOC-18)
[61]. This discrepancy seems to be related to absorption characteristics
and kinetics of NO release of different donors, as well as the micro-
environment and concentration of reducing agents. S-nitrosylation is
not the only PTM of DR4, it could be also S-palmitoylated, a process
that targets the receptor to raft nanodomains and confers efﬁcient
TRAIL-induced cell death [54].
2.2. S-nitrosylation of Fas
We have shown that the NO donor glyceryl trinitrate or GTN
sensitizes human colorectal cancer cells to Fas agonist-inducing
apoptosis [45]. Bonavida and collaborators have shown that S-ni-
trosylation of Ying Yang 1 (YY1), a repressive transcription factor
of Fas receptor, inhibits the function of this factor that results in
the increase of Fas level of expression and cancer cell sensitizationto Fas agonists [18]. Our team has shown that GTN S-nitrosylated
Fas in colorectal cancer cells on both cysteines 199 and 304, and
the pro-apoptotic functional effect of S-nitrosylation on Fas was
only demonstrated for cysteine 304. We also demonstrated that
S-nitrosylation of Fas targets the receptor to raft nanodomains and
promotes its aggregation without affecting its plasma membrane
expression [31]. Of note, cysteine residues can be a site for other
post-translational modiﬁcations. S-palmitoylation of Fas on both
cysteines 199 and 194 (by a palmitoyl acyltransferase) has also
been reported as an essential PTM for the redistribution of this
receptor into lipid rafts, a mandatory step for the death signal
transmission that increases Fas expression and thereby circum-
vents its degradation by lysosomal proteolysis [5,55].
In conclusion, the PTM of DR4 and Fas through either S-ni-
trosylation or S-palmitoylation renders cancer cells more sensitive
to receptor-induced cell death (Fig. 1). Although the functional
relevance of the S-nitrosylation of several proteins of the TNF-
superfamily signaling pathways have been assessed in response to
nitrosative stress, the antitumoral properties of NO are not re-
stricted to PTM by S-nitrosylation. An increase in intracellular le-
vels of NO following NO donor administration or nitric oxide
synthase 3 (NOS3) overexpression has been shown to increase Fas,
cFLIP-L expression levels and cell death sensitization in a number
of human hepatoma cell lines and mouse models. A similar en-
hanced expression of DR4 and TNFR1 was also observed [13].3. S-nitrosylation of proteins involved in death receptor sig-
naling pathways
3.1. S-nitrosylation of caspases
During apoptosis, caspase zymogens are either cleaved by auto-
proteolysis or cleaved by other caspases to form active tetrameric
enzymes. All caspases have a catalytic site cysteine, critical for enzy-
matic activity, that could be S-nitrosylated. S-nitrosylation and deni-
trosylation of cysteine thiol group in the active site of caspase re-
presents a potent mechanism for NO regulation of apoptosis. S-ni-
trosylation of the catalytic site cysteine of caspase-1 and -3 in human
endothelial cells inhibits their activity leading to TNFα-mediated cell
death [10]. Furthermore, high concentrations of NO inhibit, in vitro,
7 recombinant caspases (caspases-1, 2, 3, 4, 6, 7, and 8) [33]. However,
NO-mediated S-nitrosylation of cellular endogenous caspases is not
conﬁrmed for all of these enzymes. NO can prevent apoptosis in non-
cancerous hepatocyte through S-nitrosylation of caspase-8 and cas-
pase-3 [27,28]. In addition, caspase-3 was found to be S-nitrosylated in
unstimulated lymphocyte cell lines. Upon Fas stimulation then cas-
pase-3 undergoes denitrosylation and subsequent activation [37]. In
addition, S-nitrosylation and inhibition of caspase 9 has been de-
monstrated in cholangiocarcinoma cells [63].
We have shown that NO can inhibit and activate caspases. In-
deed, the NO donor glyceryl trinitrate activated caspase-1 and -10
and inhibited, at the same time, caspase-3. Together, these events
lead to colorectal cell apoptosis [45]. Our results suggest that NO
can target some caspases but not all. Some may be sensitive and
some others more resistant to S-nitrosylation or also subjected to
rapid changes of S-nitrosylation/denitrosylation processes along
the signaling cascade. Along these lines, X-linked inhibitor of
apoptosis protein (XIAP), a member of the Inhibitor of APoptotis
(IAP) protein family which is a powerful inhibitor of caspases, has
been shown to undergo S-nitrosylation but via a trans-S-ni-
trosylation process catalyzed by caspase 3. The authors have de-
monstrated, by means of in vitro experiments, that an NO moiety
was transferred from S-nitrosylated caspase 3 to XIAP on cysteine
residue 450 but not vice-versa [47]. S-nitrosylation of XIAP has
been detected in the brain of patient suffering from
Fig. 2. S-nitrosylation in classical TNF-NF-kB signaling. When TNFα binds its receptor TNF receptor 1 (TNFR1), it stimulates the formation of complex I that results in the
recruitment of TNFR-associated via death domain (TRADD), receptor-interacting serine/threonine protein kinase 1 (RIPK1), TNFR-associated factor 2 (TRAF2), cellular in-
hibitor of apoptosis cIAPs (cIAP1 and cIAP2). The cIAPs, via their E3 ubiquitin ligases activities, promote the ubiquitination (through K63-linked ubiquitin chains) of RIPK1,
TRAF2, and themselves which subsequently allows the recruitment of other complexes. Linear ubiquitin chain assembly complex (LUBAC) associates with ubiquitin linkages
attached to cIAPs, transforming growth factor-β activated kinase (TAK1)/TAK1-binding 2 (TAB2)/TAK1 binding 3 (TAB3) associates with ubiquitin linkages attached to RIPK1
and inhibitor of kappaB alpha (IkBα) kinase (IKK) complex associates with ubiquitin linkages attached to TRAF2. LUBAC ubiquitylates (through M1-linked ubiquitin chains)
IKKγ and stably recruits the IKK complex. The IKK complex (IKKβ) is then phosphorylated by TAK1/TAB2/TAB3. IKKβ in turn phosphorylates IkBα that leads to the addition of
K48-linked ubiquitin chains and its proteasome-mediated degradation with the subsequent activation and nuclear translocation of the NF-kB transcription factor hetero-
dimer. S-nitrosylation of IKKβ subunit prevents the phosphorylation of IkBα and its degradation. S-nitrosylation of either p50–p65 NF-kB subunits inhibits DNA binding and
transcriptional upregulation of NF-kB target genes. In the absence of cIAPs or in presence of CYLD, which allows the removal of K63-linked ubiqtuitin chains, RIPK1
translocate to the cytoplasm to induce the formation and activation of complex II that leads to apoptosis.
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apoptotic function and then contributes to the degenerative pro-
cess. More recently, S-nitrosylation of XIAP cysteine 213 was found
to impair the anti-apoptotic function of XIAP (anti-caspase 3) [67].
XIAP overexpression has been associated with tumorigenesis and
survival of many malignant cells. However, S-nitrosylation of XIAP
has never been reported in cancer cells and NO-based cancer
treatment represents an interesting approach.
3.2. S-nitrosylation of cellular FLICE-inhibitory protein (cFLIP)
Death receptor signaling can also be modulated by various
proteins such as the cellular FLICE-inhibitory protein (cFLIP). At
least two variants of this protein are expressed, the short cFLIP
(cFLIP-S) and the long cFLIP (cFLIP-L). This protein has been
identiﬁed as an inhibitor of apoptosis triggered by engagement of
death receptors such as Fas or DR4. However, when overexpressed,
cFLIP-L, but not cFLIP-S has been reported to be pro-apoptotic [12].
cFLIP-L could associate with caspase-8 and exhibit a proteolytic
activity which could account for the pro-apoptotic activity ofcFLIP-L under non-physiologic conditions [44]. cFLIP can undergo
S-nitrosylation at cysteine residues 254 and 259 preventing its
degradation via the ubiquitin proteasome pathway [6]. Recently,
the same group showed that S-nitrosylation of cFLIP mediates the
receptor-interacting serine/threonine protein kinase 1 (RIPK1)
binding to induce Nuclear Factor-kappa B (NF-kB) activation and
confers resistance to apoptosis, since double mutation of cysteine
254 and 259 increased apoptosis when mammary cancer cells
were stimulated by either TNFα or FasL [60].4. TNF-superfamily signaling pathways and growth control:
role of TNFR1
The binding of TNFα to TNFR1, the major signaling receptor for
TNFα, triggers cellular responses as diverse as proliferation, dif-
ferentiation and survival predominantly which suppress apoptosis.
Signals transmitted through TNFR1 can trigger concomitantly the
classical NF-kB signaling (Fig. 2) and certain Mitogen-Activated
Protein Kinase (MAPK) pathways, such as c-Jun NH2-terminal
Fig. 3. S-nitrosylation in TNF-JNK-AP-1 signaling. Upon TNFα binding, TNFR1 activates JNK-AP-1 signaling through the association of TRADD, RIPK1 and TRAFs (especially
TRAF2) to the cytoplasmic death domain of TNFR1. TRAF2 recruits ASK1 (when released from Trx) an upstream MAP3K that can activate both JNKs (via the activation of
MKK4 and MKK7) and p38 MAPKs (via the activation of MKK3 and MKK6). The activation of JNKs leads to the activation of the transcription factor AP-1. S-nitrosylation can
stimulate (disruption of ASK1-Trx interaction) or prevent (inhibition of ASK1 and JNKs kinase activities as well as AP-1 DNA-binding ability) JNK-AP-1 signaling.
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scriptions factors NF-kB and Activator Protein-1 (AP-1) respec-
tively [4]. Through abnormal activation of NF-kB and AP-1, TNFα
contribute to tumor development [2,70].
Dysregulation of the NF-kB pathway is found in many types of
tumor. Constitutive activation of NF-kB in tumor cells can be either
the result of oncogenic mutations in the signaling molecules or
exposure to proinﬂammatory stimuli such as TNFα or other TNF
superfamily members in the tumor microenvironment. The tran-
scription factor NF-kB is a mediator of immune response. NF-kB
overactivity contributes to tumorigenesis by promoting the ex-
pression of various genes that are involved in survival, prolifera-
tion, invasion and metastasis of tumor cells [2]. Furthermore, ac-
tivation of NF-kB can prevent tumor cell death to contribute topromote tumorigenesis and confer acquired resistance following
chemotherapy. Current molecular therapy strategies such as se-
lective inhibitors of the catalytic subunit of Inhibitor of NF-kB (IkB)
kinase (IKK), consist in the inhibition of this pathway [68].
Therapies targeted toward NF-kB signaling components represent
an attractive approach for cancer treatment.
Two major protein complexes (complexes I and II) with dif-
ferent outcomes are initiated upon TNFR1 stimulation (Fig. 2).
On one hand, TNFR1 recruits adaptor proteins such as TNF re-
ceptor-1-associated death domain protein (TRADD) which func-
tions as a platform adaptator for other proteins including TNF-
receptor-associated factor (TRAF2), cellular Inhibitor of apoptosis 1
(cIAP1), cIAP2 and RIPK1 to initiate the formation of the complex I.
In complex I, RIPK1 modiﬁcation with non-degradative Lys-63
S. Plenchette et al. / Redox Biology 6 (2015) 507–515512polyubiquitin chains is critical for the activation of the NF-kB
pathway. Additional molecular complexes including IKK, trans-
forming growth factor beta-activated kinase 1 (TAK1)/TAK1 bind-
ing protein 2 (TAB2)/ TAK1 binding protein 3 (TAB3) and Linear
ubiquitin chain-assembly complex (LUBAC) are then recruited to
complex I while bound to the plasma membrane [9]. The complex
I is a driver of NF-kB activation pathway that leads to angiogenesis,
inﬂammation and cell survival responses. This process is initiated
by the IKK complex that triggers the phosphorylation of Inhibitor
of NF-kB alpha (IkBα), the NF-kB repressor, its subsequent ubi-
quitination and degradation by the ubiquitin–proteasome system
and allows the transcription factor NF-kB, held in the cytoplasm, to
translocate to the nucleus to promote gene transcription of tar-
geted genes [21,22].
On the other hand, in the absence of proper complex I forma-
tion, a second molecular complex (complex II), is formed in the
cytoplasm and initiates signals leading to cell death. Under con-
ditions where RIPK1 is deubiquitinated (by deubiquitinase cylin-
dromatosis protein (CYLD) or in the absence of cIAP1 and cIAP2),
RIPK1 then interacts with receptor-interacting serine/threonine
protein 3 (RIP3) into the complex II along with TRADD, Fas-asso-
ciated protein with death domain (FADD) and procaspase-8 [9,30].
Basically, the complex II can trigger either apoptosis or ne-
croptosis. Under certain biological contexts, when caspase-8 is
deleted or inhibited (by p35 or a pan-caspase inhibitor zVAD.fmk),
a RIP1-RIP3 dependent complex II-like called necroptosome is
formed and leads to the activation of necroptosis. In such context,
it remains to determine whether the putative S-nitrosylation of
caspase-8 could contribute to induce necroptosis. But in the pre-
sence of caspase-8, RIP1 and RIP3 are constitutively cleaved thus
sensitizing the cells to apoptosis [9].
4.1. S-nitrosylation in NF-kB signaling engaged by TNFα/TNFR1
NF-kB signaling pathway is sensitive to nitrosative stress and is
strongly correlated with NF-kB inhibition and apoptosis [39]. NF-kB
activation is tightly regulated by a variety of post-translational mod-
iﬁcations, including phosphorylation, ubiquitylation and S-nitrosyla-
tion. S-nitrosylation is now considered as an important mechanism of
inhibition of NF-kB signal transduction [38]. Several studies have de-
monstrated that NO exerts controls over NF-kB at multiple levels
within the signaling pathway through S-nitrosylation of essential
components.
S-nitrosylation of DR4 and Fas has been shown to sensitized
tumor cells to their cognate ligands; however, no such modiﬁca-
tion on TNFR1 receptor by S-nitrosylation has been reported so far.
The IKK complex is a central regulator of the classical NF-kB
pathway activation which is composed of three subunits IKKα,
IKKβ and NF-kB essential modiﬁer (NEMO or IKKγ) [20,23]. One
major function of IKKβ kinase activity is the phosphorylation and
subsequent inactivation of IkBα in response to many stimuli. Un-
der physiological conditions, as demonstrated in lung epithelial
cells and Jurkat cells, the IKKβ kinase activity is constitutively re-
pressed by S-nitrosylation at position Cysteine 179. Following
TNFα stimulation, IKKβ is denitrosylated at Cysteine 179 and al-
lows further downstream signaling [52].
Other in vitro studies demonstrated that inhibition of NF-kB
through S-nitrosylation occurred further downstream in the acti-
vation pathway at the nuclear level [38]. Within cells, NF-kB is a
dimeric transcription factor composed among ﬁve different types
of monomers (p50, p52, p65, c-Rel and RelB) with p50–p65 being
the primary mediator of NF-kB. Epithelial lung cancer cells either
treated with the NO donor S-nitrosocysteine or NO derived from
NOS2 following cytokine stimulation, had a great ability to inhibit
the heterodimeric NF-kB p50–p65 DNA-binding through S-ni-
trosylation of p50 at position Cysteine 62 [8,38]. Similarly, NF-kBp65 monomer has been found as a target of S-nitrosylation, fol-
lowing nitric oxide synthase 2 (NOS2) activity, at position Cysteine
38 [24]. In unstimulated lung cells, NF-kB p65 inactivation has
been reported to result in constitutive S-nitrosylation. However,
following stimuli exposure (such as Lipopolysaccharide (LPS)) NF-
kB p65 is denitrosylated along with NF-kB activation [25]. Thior-
edoxin, a SNO-protein denitrosylase, is responsible for TNFα
-mediated NF-kB p65 denitrosylation [26]. Both NF-kB subunits
p50 and p65 are S-nitrosylated at a cysteine in the DNA-binding
region of the Rel homology domain (RHD) conserved in all NF-kB
proteins [24,38]. These observations suggest a common mechan-
ism by which S-nitrosylation negatively regulates the DNA-bind-
ing activity of NF-kB and subsequent gene transcription. En-
dogenous NO production and NF-kB signaling pathways are re-
ciprocally regulated. Inﬂammation increases the abundance of
NOS2 gene transcription which is a NF-kB target gene and the
other way round, NO generated by NOS2 induces S-nitrosylation of
speciﬁc components of NF-kB signaling [38].
Under normal physiological conditions, NF-kB activation pre-
vents the pro-apoptotic effects of TNFα. The NF-kB pathway re-
presents a relevant therapeutic target in cancer for drug devel-
opment to inhibit tumor growth or even promote tumor regres-
sion. Promoting IKKβ, p50 or p65 S-nitrosylation and thereby
counteracting cell growth for the beneﬁt of tumor cell death ap-
pears as a general mechanism of action for a class of NO-donating
non-steroidal anti-inﬂammatory drugs (NSAIDs). The anticancer
effect of some NO-NSAIDS including NO-aspirin (NO-ASA) and NO-
naproxen in colon cancer is in part mediated by S-nitrosylation
and subsequent inhibition of NF-kB p65 subunit [7,65].
The components of NF-kB signaling targeted by S-nitrosylation
in cells appear to be cell type and nitrosative stress dependent.
4.2. S-nitrosylation in MAPK signaling engaged by TNFα/TNFR1
The MAPK signaling pathways are the result of stimulation by a
variety of growth factors, pathogens, cellular stresses and also pro-
inﬂammatory cytokines. MAPK signaling can be divided into four
independent pathways promoted through extracellular signal-
regulated kinases (ERK) 1 and 2 (ERK1/2), the Big MAP kinase-1
(BMK-1), p38 MAPK and JNK that regulate a broad range of cellular
decisions including proliferation, differentiation, apoptosis and
stress response. JNK activation broadly results in apoptosis in-
duction or promotion of cellular survival, and the choice of cell
fate decision appears to depend on the cell type and on the sti-
mulating signal [56]. Activation of JNK-AP-1 signaling depends on
various members of the MAPK family which are serine/threonine
kinases. Activation of the JNK pathway is among the most im-
portant signaling cascade induced in response of TNFα/TNFR1
stimulation. Accumulating evidence suggest that JNK-AP-1 sig-
naling may play a role in carcinogenesis. The TNFR1/MAPK kinase
7 (MMK7)/JNK/AP-1 signaling cascade has been shown to promote
epidermal neoplasia [70]. The JNK pathway activation requires a
phosphorylation signaling cascade in which MAP3Ks activates
MAP2Ks that in turn activates the terminal MAPK JNK. As shown
by many groups, S-nitrosylation mediated by NO from exogenous
sources or endogenous NOS2 expression can affect the JNK path-
way at several levels, from the upstream molecules to the tran-
scription factor AP-1 subunits (Fig. 3). Apoptosis signal-cell fate
decision results in balance control regulating kinase 1 (ASK1)
functions as a MAP3K protein in both JNK and p38 MAPK signaling
cascades [35]. It has been shown that endogenous NO production
in murine ﬁbrosarcoma L929 cells inhibits the kinase activity of
ASK1 through a S-nitrosylation mechanism, targeting Cysteine 869
of the catalytic domain. S-nitrosylation of ASK1 also disrupts the
interaction between ASK1 and downstream MAP2Ks substrates
(MKK3 or MKK6) notably involved in the activation of the p38
S. Plenchette et al. / Redox Biology 6 (2015) 507–515 513MAPK pathway [51]. In contradiction with this result, in a model of
brain ischemia-reperfusion, ASK1 S-nitrosylation mediated by
endogenous NO produced by NOS1 would facilitate ASK1 activity
to exert deleterious effects [34]. Hence, further studies are needed
to clearly determine how NO, from endogenous sources, affects
ASK1 activity in different pathological conditions. Nevertheless,
another report seems to point toward an explanation. In basal
conditions, thioredoxin (trx) acts to inhibit ASK1 activation and
subsequent enzyme activity through a direct interaction [59].
Further studies have demonstrated that the amount of NO com-
pared to the superoxide producing system would govern the
S-nitrosylation of the complex ASK1/trx (i.e. subsequent disruption
and inactivation of ASK1) [69].
JNK is a subfamily of MAPK protein composed of three isoforms
(JNK1, JNK2 and JNK3) with splice variants. Upon activation by
upstream kinases, JNK proteins mediate phosphorylation and ac-
tivation of transcription factors such as AP-1. Like NF-kB, AP-1
functions as dimeric complexes to trigger the expression of a wide
variety of genes. AP-1 is composed of Jun (c-Jun, Jun B, Jun D) and
Fos (c-Fos, Fos B, Fra 1, Fra 2) family members. JNK1 and JNK2 are
ubiquitously expressed in tissues while JNK3 is only expressed in
brain, heart and testes. Opposing effects have been reported as
regard to JNK1 and JNK2 which could act as either pro-tumoral or
anti-tumoral kinases. All 3 JNK proteins are S-nitrosylated upon
NO generation via interferon gamma (IFNγ)-induced NOS2 or
SNAP NO-donor in murine microglial cells thus suppressing their
interaction and kinase activity toward downstream substrate like
c-Jun [49,50,57]. In addition, NO can negatively regulate AP-1 DNA
binding. The DNA binding activity of c-Jun and c-Fos, major com-
ponents of AP-1, has been shown to be dependent on the redox
status of c-Jun cysteine 272 and c-Fos cysteine 154 [48]. Although
the S-nitrosylation of these cysteine residues more likely explains
how NO affects AP-1 function, the S-nitrosylation of c-Jun and
c-Fos has not been clearly evidenced yet.5. Concluding remarks
The classical homeostasis control system depends on a ﬁne
balance between cell death and survival signaling. Endogeneous
S-nitrosylation of proteins is an important physiological process in
the maintenance of cellular homeostasis. Particularly, it con-
tributes to keep off TNF-superfamily survival pathways in the
absence of ligand. Similarly, nitrosative stress-mediated by exo-
geneous NO donors could negatively regulate these pathways.
Protein S-nitrosylation in cancer cells is receiving increasing
attention as a mechanism to regulate proteins involved in apop-
tosis and cell growth control. Redox-based modiﬁcations of cystein
thiols by S-nitrosylation have emerged as a major signaling
mechanism. S-nitrosylation appears to exert mainly a negative
regulatory effect over protein activities and function which could
have a signiﬁcant impact, either positive or negative, on cell death.
Nevertheless, several critical factors inﬂuence S-nitrosylation
of target proteins. Although it is a non-enzymatic process,
S-nitrosylation formation in a cell is not left to chance but is tightly
dependent on NO source conditions, i.e. subcellular location (e.g.
NOS proximity), concentration, time of exposure in cell, and re-
activity of the cysteine residue (for review see [40,42].
Stimulation of death receptors such as Fas, DR4 and TNFR1 can
initiate diverse cellular responses including apoptosis. TNF-super-
family cytokines including FasL, TRAIL and TNFα from the tumor mi-
croenvironment contribute to both tumor progression and antitumor
response. A growing number of studies suggest that protein S-ni-
trosylation is a key mode by which NO regulates the function of target
proteins involved in FasL/Fas, TRAIL/DR4 and TNFα/TNFR1 signaling
pathways which can sensitize cancer cells to death. For many years, abetter understanding of the regulation of these signaling pathways has
resulted in intense drug development. The antitumoral efﬁcacy of
recombinant FasL, TRAIL and TNFα ligands or derivatives, has been
evaluated in preclinical and clinical studies as monotherapy. The de-
velopment of TNFα as a systemic treatment has not been translated to
patient due to signiﬁcant hepatotoxicity and lack of efﬁcacy [53]. Si-
milar acute toxicity toward normal cells has been reported for re-
combinant FasL. However, a more promising recombinant molecule
(APO010) has been under investigation in a phase I clinical trial
(NCT00437736). However, a great step forward in the treatment of
irresectable extremity soft tissue sarcomas has been achieved in the
recent years with the addition of TNFα to isolated limb perfusion with
chemotherapy (melphalan) [64]. Despite potent antitumor activity of
TRAIL and safety toward normal tissues, recombinant TRAIL or anti-
DR4 agonistic monoclonal antibodies evaluated in clinic as single
agents are currently no effective therapies.
The design of combinatorial treatment of TNF-superfamily
based therapies with chemotherapies represents a more promis-
ing approach. Novel therapy involving a combination of TRAIL-
based therapeutic with NO donors will be of great interest in
cancer treatment. Inhibition of TNFα-induced NF-kB signaling by
pharmacological agents represents also a powerful strategy to
enhance the efﬁcacy of cancer chemotherapy. Several selective IKK
inhibitors and other compounds have been reported yet. Similarly,
S-nitrosylation of IKK subunits represents another tool to interfere
with the NF-kB pathway. Many important functional properties of
key signaling proteins are similarly affected by targeted or con-
ventional chemotherapies and NO-mediated S-nitrosylation [3].
Exploiting the redox state and bioactivity of NO, especially through
S-nitrosylation, for cancer therapy seems to be a promising strat-
egy. Nevertheless, further studies are required to determine the
safety and effectiveness of NO donors or S-nitrosylating agents.Acknowledgments
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